Abstract. In small cell lung carcinoma (SCLC), acetylcholine (ACh) is synthesized and secreted, and it acts as an autocrine growth factor through activation of its receptors, muscarinic receptor (mAChR) and nicotinic receptor (nAChR). Alteration of tumor growth by blockade of M 3 mAChR in a human SCLC cell line, NCI-H82, was investigated in the present study. We used a highly se-
Introduction
It is well established that acetylcholine (ACh) acts as a neurotransmitter in the central and peripheral nervous systems and acts via activation of the nicotinic (nAChR) and muscarinic (mAChR) receptors. The mAChRs consist of five genetically distinct subtypes: M 1 , M 2 , M 3 , M 4 , and M 5 . Among these mAChRs, M 1 , M 3 , and M 5 are coupled with the Gq type of G proteins that activate phospholipase C to commence the phosphatidylinositol triphosphate-signaling cascade. M 2 and M 4 mAChRs, on the other hand, are coupled with the Gi type of G proteins that inhibit adenylate cyclase activity (1) .
It has recently been found that ACh is present in a variety of non-neuronal cells, such as keratinocytes (2) , surface epithelium of bronchi, small and large intestine, gall bladder, vagina, skin, and pulmonary pleura (3) . The presence of ACh in non-neuronal cells suggests that ACh acts not only as a neurotransmitter but also has other functions, such as activation of the immune system (4) and induction of cell proliferation and differentiation (5) .
ACh is also found in cancer cells such as small cell lung carcinoma (SCLC) (6) , non-small cell lung carcinoma (7) , and colon cancer (8) . In cell lines of these particular cancers, expression of mAChRs, nAChRs, choline acetyltransferase (ChAT) that synthesizes ACh, and acetylcholine esterase (AChE) that degrades ACh to choline and acetic acid (1, 9, 10) indicate that ACh is locally synthesized and metabolized. Although various subtypes of the mAChRs are expressed in some of these tumor cells, M 3 mAChR appears to be mainly involved in tumor progression (11) . For example, muscarinic activation induces cell proliferation, and blocking of M 3 mAChR inhibits cell proliferation, in vitro and in vivo (7, 12, 13) . Knockdown of M 3 mAChR using small interfering RNAs (siRNAs) also results in blocked ACh-induced increase in [Ca 2+ ] i , whereas knockdown of M 1 and M 5 mAChRs appears to have no effect on calcium response (12) . Furthermore, the inhibitory potency of mAChR subtype-selective antagonists and M 3 mAChR siRNAs on ACh-increased intracellular calcium and phosphorylation of mitogen-activated protein kinase (MAPK) and Akt has also been demonstrated (12) . Furthermore, both tumor number and volume of colon cancer induced by azoxymethane were reduced in M 3 mAChR-deficient mice compared with wild-type mice (14) .
A muscarinic antagonist has been reported to have anti-tumor activity, inhibiting SCLC growth in an NCI-H82 xenograft model. In this model, darifenacin, which is clinically used to treat urinary incontinence, inhibited tumor growth at doses of 1 -3 mg/kg per day after 5 weeks of administration (12) . Darifenacin demonstrated potent antagonistic activity against M 3 mAChR, though its selectivity against other mAChRs was poor (15) . The anti-tumor efficacy of darifenacin might be mediated by blockade of M 3 mAChR, although the involvement of other subtypes of mAChRs cannot be excluded.
Recently, a potent selective M 3 muscarinic antagonist, (15) .
In order to further understand the role of M 3 mAChR in cancer cells and to explore the possible therapeutic utility of M 3 muscarinic antagonists as antitumor agents, we evaluated the effect of a selective M 3 muscarinic antagonist, J-115311, in a mouse orthotopic xenograft model of SCLC. 
Materials and Methods

Drugs
Cell culture
The human SCLC cell line NCI-H82 (American Type Cell Collection (ATCC), Manassas, VA, USA) was cultured in RPMI 1640 (ATCC) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) and 100 units/ml penicillin and 100 μg/ml streptomycin (Invitrogen). The cells were incubated at 37°C with 5% CO 2 in a humidified atmosphere.
Calcium fluorometry
Changes Changes in fluorescence were measured before and after the application of 300 μM carbachol (SigmaAldrich). The M 3 muscarinic antagonists were added to the wells 5 min prior to the application of carbachol.
Data analyses were performed using Prism (version 4.03; GraphPad Software, La Jolla, CA, USA). Data were plotted as the fluorescence changes between the relative fluorescence unit (RFU) before the application of carbachol and RFU at the maximum responses after the application of carbachol with or without several concentrations of the M 3 muscarinic antagonists. Curve fitting was achieved using nonlinear regression.
Cell proliferation and viability
Cell proliferation and viability was measured using the WST-8 assay. NCI-H82 cells were seeded at 5 × 10 3 cells/well in a 96-well plate and cultured overnight. M 3 muscarinic antagonists dissolved in dimethylsulfoxide (DMSO; Nacalai Tesque, Kyoto), at a final DMSO concentration of 0.5%, were added to the cells. The final medium volume in each well was 200 μl. At 72 h after drug application, 20 μl of WST-8 reagent (Kishida Chemical, Osaka) was added to each well. The cells were incubated for an additional 3 h and then the plates were read at an optical density of 450 nm on a microplate reader (SpectraMax ® 190, Molecular Devices).
Cell cycle analysis
The effect of J-115311 on cell cycle distribution was analyzed using BD Cycletest TM Plus DNA Reagent Kit (Becton, Dickinson and Company). NCI-H82 cells were seeded at 6 × 10 4 cells/well onto 6-well plates and allowed to adhere for 24 h. Cells were incubated with J-115311 for 48 h and were harvested by trypsinization. Cells were centrifuged for 3 min at 1200 rpm and resuspended in 1 ml of buffer solution (dimethylsulfoxide in sucrose-sodium citrate) and stored at −80°C until analysis. Cells were thawed at room temperature and centrifuged for 3 min at 5000 rpm. Supernatant was removed and 125 μl of Solution A (trypsin in spermine tetrahydrochloride detergent buffer) was added. One hundred microliters of Solution B (RNase A and trypsin inhibitor in spermine buffer) was added after 10-min incubation at room temperature. Ten minutes later, 100 μl of cold Solution C (propidium iodide in spermine buffer) was added and the cells were incubated for 15 min at 4°C. Subsequently, cell cycle distribution was analyzed by flow cytometry (BD FACSCalibur TM , Becton, Dickinson and Company).
Animal experiments
Female mice (C.B-17/Icr-scid/scidJcl; CLEA Japan, Tokyo) were housed in microisolators under controlled temperature and humidity (23 ± 2°C, 55 ± 15%), and on a 12-h light/dark cycle. Mice had access to tap water and food ad libitum. Food was prepared as a paste by mixing the powder form of CE-2 (CLEA Japan) with 1.5 times volume of water depending on the weight of the powder (e.g., 100 g/150 ml) because suppression of food intake can be caused by a mechanism-based dry mouth induced by M 3 mAChR antagonism (16, 17, 18) . All experimental procedures were approved by the Banyu Institutional Animal Care and Use Committee and were undertaken in an AAALAC-approved animal facility.
NCI-H82 cells were cultured as described above and resuspended in fresh PBS buffer at a concentration of 1 × 10 8 cells/ml. A 20-μl aliquot of this cell suspension was injected into the upper lobe of the left lung orthotopically (19) . Tumors were allowed to grow for 1 week. MicroCT images were obtained using an eXplore Locus microCT scanner (GE Healthcare, Chalfont St. Giles, UK) under the conditions of 93-μm isotropic resolution, 80 kV, and 450 μA under isoflurane anesthesia (1% -2%) in order to confirm the growth of the tumors in the lung (20) . Mice were divided into three groups (n = 7 -8) to obtain the same mean tumor volume based on the CT images. J-115311 was dissolved in 50% DMSO and 50% distilled water and administered subcutaneously at doses of 25 and 50 mg/kg for 10 days. At the end of the study, the lungs and tumors were harvested and weighed. Tumor diameters were measured with a digital caliper, and tumor volume was calculated using the following formula:
Tumor volume (mm 3 ) = length (mm) × width (mm) 2 × 0.5
Statistical analysis
Results are expressed as the mean ± S.E.M. Data analysis was performed using SAS software (SAS Institute, Cary, NC, USA). One-way analysis of variance followed by William's test was used. Values of P < 0.05 were considered statistically significant. Values for IC 50 in calcium fluorometry and cell proliferation assays were calculated by using Prism (version 4.03, GraphPad Software).
Results
Functional analysis of M 3 mAChR in NCI-H82 cells
To (Fig. 1A) . As shown in Fig. 1B , both J-115311 and darifenacin were able to completely inhibit 300 μM carbachol-induced [Ca 2+ ] i influx in a dose-dependent manner. IC 50 values for J-115311 and darifenacin were 31 and 24 nM, respectively.
Effects of M 3 muscarinic antagonists on cell proliferation and viability
The proliferation of NCI-H82 cells was suppressed in a concentration-dependent manner by the addition of J-115311. An IC 50 value of 6.2 μM was obtained, and at over 17 μM, all cells were dead. Darifenacin also suppressed cell proliferation in a concentration-dependent manner with an IC 50 value of 22 μM, but did not cause total cell death (Fig. 2) .
Effect of the M 3 muscarinic antagonist on cell cycle
The effect of J-115311 on the cell cycle was analyzed in NCI-H82 cells. As shown in Table 1 , treatment with 10 μM of J-115311 induced cell death. The percentage of cells in G1, S, and G2/M phases were decreased due to increased cell death. NCI-H82 cells inoculated into the upper lobe of the left lung orthotopically were detectable with a microCT scan 1 week after injection (Fig. 3, upper panel) . A total of 2 × 10 6 NCI-H82 cells transplanted orthotopically reached a size of 88.2 ± 23.0 mm 3 approximately 3 weeks after inoculation (Fig. 3, lower panel) .
As shown in Fig. 4 , J-115311 dose-dependently suppressed both the tumor weight (71.6 ± 13.5, 57.5 ± 17.0, and 45.2 ± 6.8 mg for the vehicle and 25 and 50 mg/kg for J-115311, respectively) and tumor volume (88.2 ± 23.0, 76.0 ± 24.0, and 50.9 ± 7.9 mm 3 for the vehicle and 25 and 50 mg/kg for J-115311, respectively). The tumor volumes in the mice treated with 50 mg/kg of J-115311 were significantly reduced when compared with the vehicle-treated group (P < 0.05), yet reduction in tumor weights in mice treated with 50 mg/kg of J-115311 did not reach statistical significance (P < 0.09, compared with the vehicle-treated group).
Discussion
Reports show that ChAT and M 3 mAChR are expressed in NCI-H82 cells (9, 12) . In the present study, we observed carbachol-induced [Ca 2+ ] i influx in NCI-H82 cells, indicating the presence of mAChRs, because carbachol is known to selectively activate mAChRs despite its lack of selectivity among the mAChRs. We demonstrated that both J-115311 and darifenacin were able to inhibit the increased [Ca ] i increase (12) . Both J-115311 and darifenacin suppressed cell proliferation in a dose-dependent manner. It is reported that endogenous ACh can be detected in the medium of cultured NCI-H82 cells incubated in the presence of neostigmine, an AChE inhibitor (6, 9). Thus, both J-115311 and darifenacin could exert their inhibitory effects on cell proliferation stimulated by endogenous ACh. J-115311 was about three times more potent than darifenacin (IC 50 values: 6.2 and 22 μM for J-115311 and darifenacin, respectively) at inhibiting cell proliferation. However, J-115311 and darifenacin do have a similar potency for inhibiting carbachol-induced [Ca 2+ ] i influx in the same cell line. It is known that the release of ACh from the parasympathetic nerves is controlled by M 2 autoreceptors located on the nerves (21, 22) and that inhibition of these autoreceptors leads to the release of ACh. It is also reported that the M 2 mAChR antagonist significantly increases proliferation of H1694 cells, an SCLC cell line, which suggests that the presence of the M 2 autoreceptor regulates cell proliferation in lung cancer cells (23) . Furthermore, it is reported that forskolin, which induces the elevation of cAMP level by activating adenylate cyclase, induces lung cancer cell proliferation (24, 25) . M 2 mAChR is coupled with the Gi type of G protein that inhibits adenylate cyclase activity, which leads to a decrease of cAMP levels. Thus, antagonism of M 2 mAChR leads to cell proliferation. Expression of M 2 mAChR mRNA in NCI-H82 cells by reverse transcription-PCR has been reported under normal conditions (26) . Darifenacin exerts relatively strong antagonism on M 2 mAChR compared with that of J-11531 (M 2 /M 3 = 56 and M 2 /M 3 = 98 for darifenacin and J-115311, respectively) (15) . The difference in IC 50 values of J-115311 and darifenacin to inhibit cell proliferation might be due to the difference in selectivity to M 2 mAChR-regulating cell proliferation.
In the present study, discrepancy of IC 50 values between the [Ca 2+ ] i influx assay and the cell proliferation assay was observed. Song et al. showed that darifenacin totally inhibited ACh-induced [Ca 2+ ] i influx in NCI-H82 cells at the concentration of 300 nM (26) . In their study, the IC 50 value for the cell proliferation assay should be ] i influx at around 100 nM. The IC 50 value for cell proliferation was 22 μM after 3 days of treatment with darifenacin. Cell growth is shown as the percentage of untreated control wells in this study. That is, the value of 0% means total cell death. On the other hand, cell growth was shown as relative values at day 0 in their study. Considering these differences in study conditions, the IC 50 values for the cell proliferation assay were equal between the two studies.
J-115311 caused cell death without causing cell cycle arrest. Therefore, cell death caused by inhibition of M 3 mAChR appeared to be mediated by the inhibition of the intracellular signal transduction system independent of cell cycle regulation. It is reported that ACh induces phosphorylation of Akt in NCI-H82 cells and that the M 3 mAChR antagonist 4-DAMP inhibits this phosphorylation (12) . Activation of phosphatidylinositol 3-kinase (PI3K) converts phosphatidylinositol-bis-phosphate to phosphatidylinositol-tri-phosphate (PIP 3 ). PIP 3 leads to the recruitment of 3-phosphoinositide-dependent protein kinase-1 to the proximal side of the plasma membrane, which results in the activation of Akt (27) . Involvement of the PI3K/Akt pathway in the regulation of lung cancer cell proliferation is reported (28, 29) . Thus, the PI3K/Akt pathway might be involved also in the proliferation of NCI-H82 cells. It is also reported that carbachol activates MAPK phosphorylation in NCI-H82 cells, and the M 3 mAChR antagonist inhibits this phosphorylation both in vitro and in vivo (12) . The extracellular-signal-regulated kinase (ERK) pathway is reported to be one of the intracellular signaling pathways downstream of M 3 mAChR in colon cancer cells, when epidermal growth factor receptor (EGFR) is co-expressed with M 3 mAChR (30). In NCI-H82, it has been reported that expression of EGFR is below the detection level. In spite of low expression levels, the EGFR tyrosine kinase inhibitor gefitinib inhibited phosphorylation of ERK in NCI-H82 cells, suggesting the presence of a functional EGFR in NCI-H82 (31) . Involvement of the ERK pathway is not excluded in the proliferation of NCI-H82 cells. In the present study, we did not measure the activity of these signaling mechanisms; further studies will be necessary to clarify the signaling mechanisms downstream of M 3 mAChR blockade.
In general, growth rates of tumor cells transplanted subcutaneously are slow (32) . It took 2 -3 weeks for 2 × 10 7 cells NCI-H82 cells inoculated into subcutaneous tissue to reach about 100 mm 3 in size. However, fewer amounts of cells (2 × 10 6 ) transplanted orthotopically grew faster than those transplanted subcutaneously. This difference in growth speed of the cells between orthotopical and ectopical transplantation might be due to differences in the microenvironment of the tissues. It is well established that orthotopic xenograft mouse models of human tumors are capable of reproducing the histology and metastatic pattern of most human tumors (32 -36) . For example, the metastatic sites of human lung cancer are the bone, lung (contralateral), brain, and liver. In an orthotopic xenograft mouse model of lung caner, the metastatic sites are the bone, lung (contralateral), lymph node, and pleura (34) . In this study, the selective M 3 muscarinic antagonist J-115311 inhibited tumor growth in an orthotopic xenograft model of SCLC, thus indicating that blockade of M 3 mAChR was effective at suppressing tumor growth in a similar microenvironment to the primary target organ in humans.
Human breast tumor tissue obtained from cancer patients (stage I) was found to overexpress M 3 which was not detectable in normal breast tissue (37) . AChE activity was decreased in airway surface fluid obtained from squamous cell carcinoma patients (38) . It is also reported that reducing AChE activity with AChE inhibitors led to tumor growth in a rat mammary tumor model (39) . These results suggest that activation of local cholinergic tone positively regulates tumor growth, although it is not clear how/why the local cholinergic tone increases such growth. Activated cholinergic tone could be mediated by the mAChRs, especially M 3 mAChR for tumor growth. Furthermore, involvement of M 3 mAChR in SCLC cell adhesion and migration is also reported (40) .
In summary, a selective muscarinic M 3 antagonist, J-115311, reduced tumor growth not only in vitro but also in an orthotopic xenograft mouse model of SCLC. Therefore, muscarinic M 3 antagonists could be potent therapeutic targets for cancer treatment in the future.
